Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Interferons for Covid-19: A Literature Review on Their Therapeutic Potential, Clinical Data and Challenges

Pramod Yadav
* ORCID logo ,
Vishal Chandra
,
Vikas Raghuvanshi
,
Amarjeet Yadav
,
Adhishree Yadav
,
Samim Ali
,
Vivek Mani Tripathi
Version 1 : Received: 5 July 2023 / Approved: 5 July 2023 / Online: 6 July 2023 (07:00:39 CEST)

A peer-reviewed article of this Preprint also exists.

Pramod, Y.; Vishal, C.; Vikas, R.; Amarjeet, Y.; Adhishree, Y.; Samim, A.; Vivek Mani, T. Interferons as a Potential Therapeutic Drug for COVID-19: A Literature Review of Mechanisms, Current Clinical Trials, and Challenges. Journal of Community Medicine and Health Solutions 2023, 4, 048–056, doi:10.29328/journal.jcmhs.1001035. Pramod, Y.; Vishal, C.; Vikas, R.; Amarjeet, Y.; Adhishree, Y.; Samim, A.; Vivek Mani, T. Interferons as a Potential Therapeutic Drug for COVID-19: A Literature Review of Mechanisms, Current Clinical Trials, and Challenges. Journal of Community Medicine and Health Solutions 2023, 4, 048–056, doi:10.29328/journal.jcmhs.1001035.

Abstract

The 2019 COVID-19 pandemic caused by SARS-CoV-2 has resulted in many fatalities worldwide. Despite various types of supportive care, mortality rates for patients with comorbidities remain high. To explore alternative treatment options, interferons (IFNs) have emerged as promising therapeutic drugs for SARS-CoV-2. This review aims to investigate the potential of IFNs as a drug with details on their mechanisms of action, and available data on their use with ongoing clinical trials, results, potential limitations, and challenges. Recently published research articles, which were systematically searched through online databases, have been selected and found that IFNs have colossal potential in treating SARS-CoV-2 infection by modulating the host's immune response and inhibiting viral replication and decreasing the severity of disease and hospitalization (p = 0.03, ±0.05) and (p = 0.04, ±0.05) respectively. However, due to less available data, more controlled and randomized trials are needed to confirm the efficacy and safety of IFN therapy. The optimal dosing and duration of IFN therapy also remain to be determined. Although further research is needed the wait for ongoing clinical trial results under investigation is also important for a better understanding of IFN therapy.

Keywords

Therapeutic; COVID-19; Immune response; Clinical trials; Antiviral therapy

Subject

Biology and Life Sciences, Virology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.